Niemann-Pick disease is a group of rare inherited conditions that affect how the body breaks down fats inside cells, leading to a harmful buildup that can damage the brain, nerves, liver, spleen, and other organs over time.

Understanding Niemann-Pick Disease

Niemann-Pick disease refers to a collection of rare genetic conditions that interfere with the body’s ability to process and use certain types of fats, including cholesterol (a waxy substance found in all cells) and lipids (fatty materials such as oils and waxes). When these fats cannot be broken down properly, they accumulate inside cells, particularly in structures called lysosomes, which are tiny compartments within cells responsible for breaking down and recycling various substances.^[1]

This buildup of fats causes cells to malfunction and eventually die. As more and more cells are affected, the organs where these cells reside begin to fail. The disease can impact multiple parts of the body, including the brain, nerves, liver, spleen, bone marrow, and sometimes the lungs. The progression and severity of symptoms depend on which type of Niemann-Pick disease a person has and how quickly the fat accumulation occurs.^[1]

There are three main types of Niemann-Pick disease, labeled A, B, and C. Types A and B are caused by problems with an enzyme called acid sphingomyelinase, which normally breaks down a fatty substance called sphingomyelin that exists in every cell of the body. Type C, on the other hand, results from defects in proteins that help transport cholesterol and other fats within cells. While all three types involve fat accumulation, they differ significantly in their symptoms, age of onset, and severity.^[2]

How Common Is Niemann-Pick Disease?

Niemann-Pick disease is extremely rare, affecting a small number of people worldwide. Type C is estimated to affect approximately one in every 100,000 children, making it exceptionally uncommon.^[10] The disease has been reported across all continents, including North America, South America, Europe, Africa, Asia, and Australia, indicating that it affects people of all ethnic backgrounds and geographical locations.^[4]

However, certain populations show a higher incidence of specific types. Type A and Type B are more common among people of Ashkenazi Jewish (Eastern European Jewish) descent. Type C appears more frequently among Puerto Ricans of Spanish descent. There is also a variant called Type C1, which has only been observed in French Canadian people living in Yarmouth County, Nova Scotia, suggesting that genetic factors and ancestral background play a role in who develops the disease.^[6]

Medical professionals believe that the actual number of people affected by Niemann-Pick disease may be higher than reported. Many cases may go undiagnosed or be misdiagnosed as other conditions because the symptoms can be similar to other diseases and because awareness of this rare condition is limited among healthcare providers. Only about 500 patients with Type C have been identified worldwide, though the true number is likely greater.^[17]

What Causes Niemann-Pick Disease?

Niemann-Pick disease is caused by genetic mutations, which are changes in the DNA instructions that tell the body how to make certain proteins or enzymes. These mutations are inherited from parents in what scientists call an autosomal recessive pattern. This means that a child must inherit two copies of the mutated gene—one from each parent—for the disease to develop.^[3]

For Types A and B, the mutations occur in a gene called SMPD1. This gene provides instructions for making the enzyme acid sphingomyelinase, which is responsible for breaking down sphingomyelin into smaller components. When both copies of this gene are defective, the body cannot produce enough of this enzyme, or the enzyme doesn’t work properly. As a result, sphingomyelin accumulates in cells, particularly in specialized immune cells called macrophages, which then deposit in various organs throughout the body.^[2]

Type C is different—it’s caused by mutations in either the NPC1 or NPC2 genes. These genes provide instructions for making proteins that help transport cholesterol and other lipids within cells, particularly moving them out of the lysosomes where they are processed. When these proteins don’t work correctly, cholesterol and other fats become trapped inside the lysosomes, causing them to accumulate to toxic levels. This type of defect means that Type C is now considered a separate disease from Types A and B, even though they share the Niemann-Pick name.^[3]

Who Is at Risk?

The primary risk factor for Niemann-Pick disease is having parents who both carry a mutated gene for the condition. Because the disease follows an autosomal recessive inheritance pattern, children are only at risk when both parents pass on a defective gene. If only one parent is a carrier, their children will not develop the disease, though they may become carriers themselves.^[3]

Certain ethnic and geographical groups face higher risks for specific types of the disease. Families of Ashkenazi Jewish descent have a notably higher risk of Types A and B. In these communities, the frequency of carriers is higher than in the general population, increasing the likelihood that two carriers will have children together. Similarly, Puerto Ricans of Spanish ancestry have an elevated risk for Type C, and French Canadians from Nova Scotia face increased risk for the C1 variant.^[6]

Family history is another important risk factor. If a family has already had one child with Niemann-Pick disease, the parents are confirmed carriers, and each subsequent child has the same 25% risk of inheriting the condition. Families with a history of unexplained infant deaths, developmental delays, or neurological problems in children may also have undiagnosed cases of Niemann-Pick disease in their family tree, placing current and future children at potential risk.^[2]

Recognizing the Symptoms

The symptoms of Niemann-Pick disease vary widely depending on the type and severity of the condition. In general, symptoms relate to the progressive worsening of nerve and brain function, as well as the enlargement and dysfunction of organs where fats accumulate.^[1]

Type A, the most severe form, typically appears in the first few months of life. Infants may show signs of progressive weakness, feeding difficulties, and failure to gain weight or grow properly. By around three to six months of age, the abdomen becomes noticeably swollen due to enlargement of the liver and spleen. The lymph nodes may also swell. These babies experience profound brain damage, losing developmental milestones they may have briefly achieved. Most tragically, children with Type A rarely survive beyond 18 months of age.^[1]

Type B usually develops later, often appearing in the pre-teen years, though symptoms may not become apparent for several years after birth. Children with Type B may experience a lack of muscle control during voluntary movements, known as ataxia, which makes walking unsteady and coordination difficult. They may develop peripheral neuropathy, which is damage to nerves outside the brain and spinal cord, causing tingling, numbness, or weakness in the hands and feet. The liver and spleen become enlarged, and lung problems can develop, sometimes requiring supplemental oxygen. Unlike Type A, the brain is generally less affected in Type B, allowing for better survival and quality of life.^[12]

Type C can appear at any age, from infancy through adulthood, with symptoms that are highly variable. In infants, it may first show up as jaundice (yellowing of the skin and eyes) or an enlarged spleen. School-age children often develop neurological problems first, including difficulty with learning, clumsiness, problems with balance and walking, and trouble with fine motor skills like writing. A very characteristic sign is vertical supranuclear gaze palsy, which means difficulty moving the eyes up and down. Over time, speech becomes slurred, swallowing becomes difficult, and involuntary muscle contractions called dystonia may cause abnormal postures.^[2]

Many people with Niemann-Pick disease also experience vision problems, hearing loss, and increased sensitivity to touch. Sleep disturbances are common, with some patients experiencing sleep inversion—being awake at night and sleepy during the day. Some individuals develop a unusual symptom called gelastic cataplexy, where they suddenly lose muscle tone and may collapse when they laugh. Mental health problems, including depression, paranoia, hallucinations, and behavioral issues, can also occur, particularly in older patients with Type C.^[1][3]

During an eye examination, doctors may observe specific changes. In some cases, there is clouding of the cornea (the clear front part of the eye). A characteristic finding called a “cherry-red halo” may develop around the center of the retina (the light-sensitive tissue at the back of the eye). These eye findings can provide important clues to the diagnosis.^[12]

Can Niemann-Pick Disease Be Prevented?

Currently, there is no way to prevent Niemann-Pick disease once a child has inherited the genetic mutations from both parents. The disease begins before birth, as the genetic defects are present from conception. However, there are strategies that families at risk can use to make informed decisions about having children.^[3]

Genetic counseling is an important resource for families with a history of Niemann-Pick disease or for individuals from high-risk ethnic groups. Genetic counselors can explain the inheritance patterns, assess the risk of having an affected child, and discuss testing options. Carrier testing, which uses DNA analysis of a blood sample, can determine whether someone carries a mutation for Niemann-Pick disease, even if they have no symptoms themselves.^[7]

For couples who are both carriers, prenatal testing options are available during pregnancy. Amniocentesis involves taking a sample of the fluid surrounding the baby in the womb, while chorionic villus sampling takes a small piece of the placenta. Both procedures can determine whether the developing baby has inherited the genetic mutations for Niemann-Pick disease. These tests allow parents to make informed decisions about the pregnancy and to prepare medically and emotionally if the baby is affected.^[6]

Unfortunately, there are no lifestyle changes, dietary modifications, or supplements that can prevent the disease or stop the accumulation of fats in cells once the genetic defects are present. Restricting dietary fat intake does not prevent the buildup because the problem lies in how the body’s cells process fats internally, not in the amount of fat consumed.^[12]

How the Disease Affects the Body

Understanding what happens inside the body helps explain why Niemann-Pick disease causes such diverse symptoms. At the cellular level, the disease disrupts normal metabolic processes—the chemical reactions that keep cells alive and functioning.^[2]

In Types A and B, the missing or malfunctioning acid sphingomyelinase enzyme means that sphingomyelin cannot be broken down into its components: ceramide and phosphocholine. Instead, sphingomyelin and related lipids begin to accumulate inside the lysosomes of cells. Macrophages, which are immune cells that normally clean up cellular debris, become engorged with these fatty substances. These “lipid-laden” macrophages deposit throughout the body, particularly in the liver, spleen, lungs, and bone marrow.^[2]

When the liver and spleen fill with these abnormal cells, they enlarge significantly, a condition called hepatosplenomegaly. This enlargement can cause the abdomen to swell and become painful, and it may reduce appetite. The enlarged spleen can trap and destroy blood platelets prematurely, leading to thrombocytopenia—a low platelet count that increases the risk of bleeding and bruising. In the bone marrow, the fatty deposits can interfere with normal blood cell production, causing cytopenias, which means low levels of various blood cell types.^[2]

When fatty deposits accumulate in the lungs, they cause interstitial lung disease, where the tissue between the air sacs becomes inflamed and scarred. This makes it harder for oxygen to pass from the lungs into the bloodstream, causing shortness of breath and requiring some patients to use supplemental oxygen. The lung damage also makes patients more susceptible to repeated respiratory infections and pneumonia.^[2]

The brain is particularly vulnerable to the effects of lipid accumulation. In Type C, cholesterol and complex lipids called gangliosides build up in brain cells, particularly affecting the cerebellum (which controls balance and coordination), the basal ganglia (which regulate movement), and the cerebral cortex (which governs thinking and memory). One research study found that toxic metabolites accumulating in Type C include not only cholesterol and sphingomyelin but also specific gangliosides like GM2 and GM3, as well as other complex lipids.^[8]

In the cerebellum, this accumulation causes ataxia—the loss of smooth, coordinated movement. Damage to the basal ganglia produces dystonia, where muscles contract involuntarily, creating twisted postures and repetitive movements. When the upper brainstem is affected, it causes the characteristic difficulty with vertical eye movements. As the disease spreads to involve more of the brain, including the cerebral cortex, it causes progressive loss of intellectual abilities, leading to dementia, and may trigger seizures.^[3]

Bone tissue can also be affected. The disease may cause enlarged bone marrow cavities, thinning of the outer layer of bone (the cortical bone), and a specific deformity of the hip bone called coxa vara, where the angle between the hip joint and the thigh bone is reduced, affecting walking ability.^[3]

The accumulation of fats triggers energy metabolism problems in brain cells. Studies have shown that affected cells struggle to produce adequate amounts of adenosine triphosphate (ATP), which is the main energy currency that powers cellular activities. Without sufficient energy, brain cells, particularly those in the cerebellum, cannot function properly and eventually die. This energy crisis contributes significantly to the progressive neurological decline seen in patients.^[9]